Covishield, Covaxin work against Alpha, Beta, Gamma, Delta variants: ICMR chief

New Delhi: Vaccines Covishield and Covaxin work against SARS-CoV-2 variants Alpha, Beta, Gamma and Delta, while effectiveness tests against the Delta Plus variant is ongoing, the government said on Friday.

There are four variants of concern of the coronavirus disease -- Alpha, Beta, Gamma and Delta -- with Delta Plus being a sub-lineage of the Delta variant which is also a variant of concern.

Addressing a press conference, ICMR Director General Balram Bhargava said reduction of neutralisation capabilities of vaccine with different variants, which is based on global literature, shows that Covaxin does not change with the Alpha variant at all and so it is same as it is with the standard strain.

"Covishield reduces slightly with Alpha, by 2.5 times. For the Delta variant, Covaxin is effective but antibody response is slightly reduced to three-fold reduction, and for Covishield, it is two-fold reduction, while in Pfizer and Moderna it is seven-fold reduction," he said.

"However, Covishield and Covaxin work against the variants of SARS-CoV-2- Alpha, Beta, Gamma and Delta -- that is well established for these two vaccines," Mr Bhargava said.

Talking about the Delta Plus variant, Mr Bhargava said it is present now in 12 countries. There are 48 cases in India in 10 states but they are very localised, the Indian Council of Medical Research (ICMR) chief added.

"The Delta Plus variant has also been isolated and cultured at ICMR-NIV, and laboratory tests to check vaccine effect on Delta Plus variant are ongoing. We should have these results in seven-10 days as to whether the vaccine is working against the Delta Plus variant," he said.

The Delta variant has about 15-17 mutations and was first reported in October last year, and it was responsible for more than 60 per cent of cases in Maharashtra in February. It has spread to 80 countries, Mr Bhargava said.

The B.1.617 strain has three subtypes B.1.617.1, B.1.617.2 and B.1.617.3 -- and B.1.617.2 (Delta variant) has been classified as a variant of concern and it has increased transmissibility, stronger binding to receptors of lung cells, potential reduction in monoclonal antibody response and potential post-vaccination immune escape, he said.

The B.1.617.2 Plus or Delta Plus variant, detected in different parts of India, characterisation of which are ongoing (three mutations), Mr Bhargava said.

There are 16 countries where more than 25 per cent of cases of Delta variant have been found, he said.

These are Australia, Bahrain, Bangladesh, India, Indonesia, Israel, Japan, Kenya, Myanmar, Peru, Portugal, Russia, Singapore, South Korea, United Kingdom, United States of America.

Mr Bhargava said that the second wave of COVID-19 is not yet over.

"We have still got 75 districts which have more than 10 per cent prevalence. We have 92 districts which have between five-10 per cent prevalence and 565 districts are less than five per cent prevalence so in large part of India second wave is over," he said.

However, these districts are important and it is possible to avert the third wave provided individuals and society adhere to protective behaviours, Mr Bhargava said.

"We must avoid mass gathering, use masks correctly and consistently, and any indicative hotspots we find they need to be immediately identified that is what we have done with Delta Plus variant, and isolated people and vaccination has been initiated for these people and district level test positivity rate is posted on the health ministry website," he said.

Data needs to clearly monitored by districts to ensure if the rate is going beyond five per cent, the ICMR chief said.

"Then we need to impose strict restrictions and that is the most important point that will guide us through the pandemic," he added.

Mr Bhargava said public health prevention strategies do not change with variants.

"Covid appropriate behaviour and vaccination has to continue but continuous monitoring of mutations is important to track vaccine escape, increased transmissibility and disease severity. The next step is, if need be, vaccine composition can be changed as per the circulating variants of interest and variants of concern that can also be done with RNA vaccines and adenovirus-based vaccine can also be modified," he said.